What's new? Log in Free sign up

Dr. Reddy's Laboratories Limited (RDY)

Company Profile

Company profile

Ticker

RDY

Exchange

Website

www.drreddys.com

CEO

Mr. Erez Israeli M.B.A.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

ALEXANDER & BALDWIN INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

43505116

RDY stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

BlackRock, Inc.

Notice of proposed sale of securities

Dr. Reddy's Holdings Ltd

Notice of proposed sale of securities

Notice of proposed sale of securities

Dr. Reddy's Holdings Ltd

MITSUBISHI UFJ FINANCIAL GROUP INC

Beneficial ownership report

Beneficial ownership report

Financial summary

Financial statements Chart RDY financial data

Quarter (USD)	Mar 23	Mar 22	Mar 21	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 23	Mar 22	Mar 21	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

RDY institutional ownership history Ownership history

14.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	226	219	+3.2%
Opened positions	32	25	+28.0%
Closed positions	25	36	-30.6%
Increased positions	94	90	+4.4%
Reduced positions	55	67	-17.9%

13F shares	Current	Prev Q	Change
Total value	1.71 tn	1.77 tn	-3.5%
Total shares	23.34 mm	24.10 mm	-3.1%
Total puts	6.10 k	2.80 k	+117.9%
Total calls	12.70 k	14.60 k	-13.0%
Total put/call ratio	0.5	0.2	+150.4%

Largest owners	Shares	Value	Change
MS Morgan Stanley	2.24 mm	$178.14 bn	+10.4%
Robeco Institutional Asset Management B.V.	2.07 mm	$164.10 bn	-0.2%
RY Royal Bank of Canada	2.00 mm	$158.51 bn	-2.9%
Renaissance Technologies	1.95 mm	$154.96 bn	-2.3%
BLK BlackRock	1.92 mm	$152.22 bn	NEW
Aikya Investment Management	1.09 mm	$17.28 bn	-21.7%
Dimensional Fund Advisors	1.06 mm	$84.20 bn	+5.6%
Vanguard	984.78 k	$78.24 bn	-5.3%
STT State Street	909.91 k	$72.29 bn	+1.9%
BAC Bank of America	858.84 k	$68.23 bn	+0.9%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	1.92 mm	+1.92 mm	NEW
BLK BlackRock	0.00	-1.80 mm	EXIT
GS The Goldman Sachs Group, Inc.	556.04 k	-427.16 k	-43.4%
Aikya Investment Management	1.09 mm	-301.79 k	-21.7%
MS Morgan Stanley	2.24 mm	+212.10 k	+10.4%
Fisher Asset Management	491.30 k	+183.15 k	+59.4%
NA.R National Bank of Canada	3.20 k	-180.92 k	-98.3%
Millennium Management	159.74 k	-172.76 k	-52.0%
Mondrian Investment Partners	0.00	-142.22 k	EXIT
JPM JPMorgan Chase & Co.	500.72 k	-138.04 k	-21.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Dr. Reddy's Laboratories Forms New Subsidiary In Finland, 'Dr. Reddy's Finland Oy', As Step-Down Wholly-Owned Entity

https://www.bseindia.com/xml-data/corpfiling/AttachLive/79ff5f5f-81a0-4bb0-a2f0-b93541f1164e.pdf

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?

Reported Thursday, Dr. Reddy's Introduces Toripalimab In India, Immuno-Oncology Drug Approved For The Treatment Of Nasopharyngeal Carcinoma

Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma

Dr. Reddy's Laboratories, Senores Pharmaceuticals Launch Ivermectin Tablets USP, 3 mg In US Market

Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To Advance Treg-Enhancing Biologics For Neurodegenerative And Autoimmune Diseases

Press releases

From Benzinga Pro

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck

Dr. Reddy's Q2 & H1FY25 Financial Results

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science. This marks the third consecutive appearance of

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Market Alert: Dr. Reddy's Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.